Benchmarking HIV Quality Measures in the US OPERA HIV Cohort

por Heglar, Robert, Mood, Rodney, Priest, Julie L, Schulman, Kathy L, Fusco, Gregory P
Publicado 2019

Switch from Tenofovir Disoproxil Fumarate to Tenofovir Alafenamide in People Living with HIV: Lipid Changes and Statin Underutilization

por Brunet, Laurence, Mallon, Patrick, Fusco, Jennifer S., Wohlfeiler, Michael B., Prajapati, Girish, Beyer, Andrew, Fusco, Gregory P.
Publicado 2021

1023. Suppressed Switch to Bictegravir/Emtricitabine/Tenofovir Alafenamide vs. Dolutegravir/Lamivudine: Virologic Failure and Durability

por Pierone, Gerald, Fusco, Jennifer S, Brunet, Laurence, Sension, Michael, Dunbar, Megan, Gruber, Joshua, Dieterich, Douglas, Fusco, Gregory P
Publicado 2023

Lipid Changes After Switch From TDF to TAF in the OPERA Cohort: LDL Cholesterol and Triglycerides

por Mallon, Patrick W G, Brunet, Laurence, Fusco, Jennifer S, Prajapati, Girish, Beyer, Andrew, Fusco, Gregory P, Wohlfeiler, Michael B
Publicado 2021

Advanced HIV Infection in Treatment-Naïve Individuals: Effectiveness and Persistence of Recommended 3-Drug Regimens

por Mounzer, Karam, Brunet, Laurence, Fusco, Jennifer S, Mcnicholl, Ian R, Diaz Cuervo, Helena, Sension, Michael, Mccurdy, Lewis, Fusco, Gregory P
Publicado 2022

1284. Suppressed Switch to DTG/3TC 2-Drug Regimen Vs. BIC- or DTG-Based 3-Drug Regimens

por Pierone, Gerald, Fusco, Jennifer S, Brunet, Laurence, Vannappagari, Vani, Sarkar, Supriya, Henegar, Cassidy, van Wyk, Jean A, Zolopa, Andrew, Fusco, Gregory P
Publicado 2022

Heavily treatment-experienced people living with HIV in the OPERA® cohort: population characteristics and clinical outcomes

por Hsu, Ricky K., Fusco, Jennifer S., Henegar, Cassidy E., Vannappagari, Vani, Clark, Andrew, Brunet, Laurence, Lackey, Philip C., Pierone, Gerald, Fusco, Gregory P.
Publicado 2023

HLA-B*57:01 screening and hypersensitivity reaction to abacavir between 1999 and 2016 in the OPERA(®) observational database: a cohort study

por Mounzer, Karam, Hsu, Ricky, Fusco, Jennifer S., Brunet, Laurence, Henegar, Cassidy E., Vannappagari, Vani, Stainsby, Chris M., Shaefer, Mark S., Ragone, Leigh, Fusco, Gregory P.
Publicado 2019

HIV retention in care: results and lessons learned from the Positive Pathways Implementation Trial

por Wohlfeiler, Michael B., Weber, Rachel Palmieri, Brunet, Laurence, Fusco, Jennifer S., Uranaka, Christine, Cochran, Quateka, Palma, Monica, Evans, Tammeka, Millner, Carl, Fusco, Gregory P.
Publicado 2022

Weight gain before and after switch from TDF to TAF in a U.S. cohort study

por Mallon, Patrick WG, Brunet, Laurence, Hsu, Ricky K, Fusco, Jennifer S, Mounzer, Karam C, Prajapati, Girish, Beyer, Andrew P, Wohlfeiler, Michael B, Fusco, Gregory P
Publicado 2021

Virologic Outcomes Among People Living With Human Immunodeficiency Virus With High Pretherapy Viral Load Burden Initiating on Common Core Agents

por Mills, Anthony M, Schulman, Kathy L, Fusco, Jennifer S, Wohlfeiler, Michael B, Priest, Julie L, Oglesby, Alan, Brunet, Laurence, Lackey, Philip C, Fusco, Gregory P
Publicado 2021

1608. Real-World Effectiveness of Long-Acting Cabotegravir + Rilpivirine in Virologically Suppressed Treatment-Experienced Individuals: Two Years of Data from the OPERA(®) Cohort

por Sension, Michael, Hsu, Ricky K, Fusco, Jennifer S, Brunet, Laurence, Cochran, Quateka, Sridhar, Gayathri, Vannappagari, Vani, van Wyk, Jean A, Wohlfeiler, Michael B, Fusco, Gregory P
Publicado 2023

1028. Real-World Use of Long-Acting Cabotegravir + Rilpivirine in People with HIV with Detectable Viral Loads at Initiation: Findings from the OPERA(®) Cohort

por Hsu, Ricky K, Sension, Michael, Fusco, Jennifer S, Brunet, Laurence, Cochran, Quateka, Sridhar, Gayathri, Vannappagari, Vani, van Wyk, Jean A, Wohlfeiler, Michael B, Fusco, Gregory P
Publicado 2023

Virologic Outcomes Among ART-Naïve Individuals Initiating Dolutegravir, Elvitegravir, Raltegravir or Darunavir: An Observational Study

por Mills, Anthony M., Brunet, Laurence, Fusco, Jennifer S., Wohlfeiler, Michael B., Garris, Cindy P., Oglesby, Alan K., Mrus, Joseph M., Lackey, Philip C., Fusco, Gregory P.
Publicado 2019

1582. Real-World Use of Long-Acting Cabotegravir + Rilpivirine in the US: Effectiveness in the First Year

por Sension, Michael G, Hsu, Ricky K, Fusco, Jennifer S, Brunet, Laurence, Cochran, Quateka, Uranaka, Christine, Sridhar, Gayathri, Vannappagari, Vani, Zolopa, Andrew, van Wyk, Jean A, McCurdy, Lewis, Fusco, Gregory P, Wohlfeiler, Michael B
Publicado 2022